Good MorningEquity markets rebounded on Wednesday following better-than-expected results from Target. The big box retailer reported strength on the top and bottom lines and maintained its guidance for the year. The caveat is that guidance for the 2nd quarter was reduced due to weakening consumer trends, and the weakness may not be contained to the quarter. If the weakness lingers, and there is no reason to think it won't, Target will reduce its guidance later in the year.
The S&P 500 gained more than 1.0% at the day's high to confirm support at the 30-day moving average. However, the move was capped by resistance at the 4,150 level and may not get any higher. The 4,150 level has been an impossible line for the market to cross for over a year, and nothing in the outlook says that will change now. Even if the index can grind higher, the 4,300 is another line in the sand that will cap gains unless the outlook for the 2nd half begins to improve. Featured: Biden To Unleash "Choke Point" Operation On America? (InvestorPlace) 
|
Tech | | |
Whether you believe markets are always efficient, or whether you believe some stocks are mispriced, you undoubtedly want to buy low and sell high.
Some stocks are considered mispriced if they are undervalued, relative to their intrinsic value. Typically, value sectors include utilitie... Read the Full Story |
|
From Our PartnersAnalysts are screaming from the rooftops as the market is warming up to become one of the most exciting money-making opportunities of our lifetimes. We just unveiled our top 5 publicly traded gold companies. Some picks have extremely safe risk profiles while others are still dirt-cheap lotto tickets that can easily 10x from here. Nevertheless, we believe this portfolio underpins all of the life-changing gold opportunities ahead. This is your chance to amass something 99% of investors don't have – a true gold portfolio. | | | | Click here to get our top picks- absolutely free. |
|
Markets | | |
Shares of video game developer Unity Software Inc. (NYSE: U) are trading for the same price this time last year. After reaching all-time highs in November of 2021, the San Francisco headquartered stock was abruptly decimated, like many of its tech brethren. This time last year, investors were... Read the Full Story |
|
Markets | | |
Whether measured in Celsius or Fahrenheit, Celsius Holdings, Inc. (NASDAQ: CELH) is red hot!
Shares of the healthy energy drink maker soared to an all-time high last week following another outstanding earnings report. After rising 48% in 2021 and 40% last year, the stock is up more than 20% year-... Read the Full Story |
|
From Our PartnersThe average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
To break China's monopoly, the U.S. is extending strong financial support for increased DOMESTIC production of the energy metal. | | | | See How This Could Open Up New Opportunities in the U.S. Lithium Sector |
|
Markets | | | Russia agreed to a two-month extension of a deal that has allowed Ukraine to ship grain through the Black Sea to parts of the world struggling with hunger, Turkish President Recep Tayyip Erdogan announced Wednesday, a boost to global food security after the war drove up prices.Turkey and the U.N. br... Read the Full Story |
|
Markets | | | A dozen poor countries are facing economic instability and even collapse under the weight of hundreds of billions of dollars in foreign loans, much of them from the world’s biggest and most unforgiving government lender, China Read the Full Story |
|
From Our Partnerset real-time financial news and market data with MarketBeat All Access. Monitor your portfolio and the markets. Access our top stock picks, unbeatable research tools, best-in-class stock screeners, and proprietary research reports. Claim your $200 account credit and free 30-day trial subscription today.
| | Claim Your $200 MarketBeat Account Credit |
|
Markets | | | Months before an election, New Zealand’s government is offering some modest financial relief to many people by making most prescription medicines free and increasing subsidies for childcare and public transportation Read the Full Story |
|
Markets | | | Target on Wednesday reported another quarterly profit decline and issued a cautious sales and profit outlook for the current period.The Minneapolis company is dealing with rising costs, which includes rising theft as a big factor, and consumers who have become more cautious about spending.The compan... Read the Full Story |
|
Markets | | | Japan’s economy grew at an annual pace of 1.6% in the quarter through March as private demand rebounded after COVID-19-related restrictions were eased, according to data released Wednesday.Real gross domestic product, which measures the sum value of a nation’s products and services, grew 0.4% in Jan... Read the Full Story |
|
Markets | | |
Target (NYSE: TGT) reported a better-than-expected quarter driven by the underlying momentum within the US economy. That’s the good news. The bad news is that outlook is weak, echoing home improvement retailer Home Depot (NYSE: HD), and gives further evidence of a looming recession in the US... Read the Full Story |
|
Markets | | |
Shares of Siemens Aktiengesellschaft (OTCMKTS: SIEGY) showcased a massive 78% rally after 2022, full of natural growth, paired with enriched multiples on these expanding financials. Today, Siemens chart shows that the stock is consolidating around the $77-$80 range as investors look for ... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. | | View Today's Stock Pick |
|
